DYAI

Dyadic International, Inc. (NASDAQ:DYAI) is a biotechnology platform company founded in 1979 and headquartered in Jupiter, Florida. The company went public in 2008 and has evolved from its original focus on industrial enzymes to become a specialized biotechnology firm developing advanced protein production platforms. Dyadic's core innovation is its proprietary C1 platform technology, which enables rapid and cost-effective production of complex proteins for pharmaceutical, biotechnology, and alternative protein applications. The company has successfully completed its first human clinical trial and is now pursuing multiple commercial opportunities across human health, animal health, and alternative protein markets.